1 PROteolysis Targeting Chimera (PROTAC) Market Overview 1.1 PROteolysis Targeting Chimera (PROTAC) Product Overview 1.2 PROteolysis Targeting Chimera (PROTAC) Market Segment by Type 1.2.1 ARV-110 1.2.2 ARV-471 1.2.3 KYM-001 1.2.4 Others 1.3 Global PROteolysis Targeting Chimera (PROTAC) Market Size by Type 1.3.1 Global PROteolysis Targeting Chimera (PROTAC) Market Size Overview by Type (2016-2027) 1.3.2 Global PROteolysis Targeting Chimera (PROTAC) Historic Market Size Review by Type (2016-2021) 1.3.2.1 Global PROteolysis Targeting Chimera (PROTAC) Sales Breakdown in Volume by Type (2016-2021) 1.3.2.2 Global PROteolysis Targeting Chimera (PROTAC) Sales Breakdown in Value by Type (2016-2021) 1.3.2.3 Global PROteolysis Targeting Chimera (PROTAC) Average Selling Price (ASP) by Type (2016-2021) 1.3.3 Global PROteolysis Targeting Chimera (PROTAC) Forecasted Market Size by Type (2022-2027) 1.3.3.1 Global PROteolysis Targeting Chimera (PROTAC) Sales Breakdown in Volume by Type (2022-2027) 1.3.3.2 Global PROteolysis Targeting Chimera (PROTAC) Sales Breakdown in Value by Type (2022-2027) 1.3.3.3 Global PROteolysis Targeting Chimera (PROTAC) Average Selling Price (ASP) by Type (2022-2027) 1.4 Key Regions Market Size Segment by Type 1.4.1 North America PROteolysis Targeting Chimera (PROTAC) Sales Breakdown by Type (2016-2021) 1.4.2 Europe PROteolysis Targeting Chimera (PROTAC) Sales Breakdown by Type (2016-2021) 1.4.3 Asia-Pacific PROteolysis Targeting Chimera (PROTAC) Sales Breakdown by Type (2016-2021) 1.4.4 Latin America PROteolysis Targeting Chimera (PROTAC) Sales Breakdown by Type (2016-2021) 1.4.5 Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Sales Breakdown by Type (2016-2021) 2 Global PROteolysis Targeting Chimera (PROTAC) Market Competition by Company 2.1 Global Top Players by PROteolysis Targeting Chimera (PROTAC) Sales (2016-2021) 2.2 Global Top Players by PROteolysis Targeting Chimera (PROTAC) Revenue (2016-2021) 2.3 Global Top Players PROteolysis Targeting Chimera (PROTAC) Price (2016-2021) 2.4 Global Top Manufacturers PROteolysis Targeting Chimera (PROTAC) Manufacturing Base Distribution, Sales Area, Product Type 2.5 PROteolysis Targeting Chimera (PROTAC) Market Competitive Situation and Trends 2.5.1 PROteolysis Targeting Chimera (PROTAC) Market Concentration Rate (2016-2021) 2.5.2 Global 5 and 10 Largest Manufacturers by PROteolysis Targeting Chimera (PROTAC) Sales and Revenue in 2020 2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in PROteolysis Targeting Chimera (PROTAC) as of 2020) 2.7 Date of Key Manufacturers Enter into PROteolysis Targeting Chimera (PROTAC) Market 2.8 Key Manufacturers PROteolysis Targeting Chimera (PROTAC) Product Offered 2.9 Mergers & Acquisitions, Expansion 3 PROteolysis Targeting Chimera (PROTAC) Status and Outlook by Region 3.1 Global PROteolysis Targeting Chimera (PROTAC) Market Size and CAGR by Region: 2016 VS 2021 VS 2026 3.2 Global PROteolysis Targeting Chimera (PROTAC) Historic Market Size by Region 3.2.1 Global PROteolysis Targeting Chimera (PROTAC) Sales in Volume by Region (2016-2021) 3.2.2 Global PROteolysis Targeting Chimera (PROTAC) Sales in Value by Region (2016-2021) 3.2.3 Global PROteolysis Targeting Chimera (PROTAC) Sales (Volume & Value) Price and Gross Margin (2016-2021) 3.3 Global PROteolysis Targeting Chimera (PROTAC) Forecasted Market Size by Region 3.3.1 Global PROteolysis Targeting Chimera (PROTAC) Sales in Volume by Region (2022-2027) 3.3.2 Global PROteolysis Targeting Chimera (PROTAC) Sales in Value by Region (2022-2027) 3.3.3 Global PROteolysis Targeting Chimera (PROTAC) Sales (Volume & Value), Price and Gross Margin (2022-2027) 4 Global PROteolysis Targeting Chimera (PROTAC) by Application 4.1 PROteolysis Targeting Chimera (PROTAC) Market Segment by Application 4.1.1 Oncology 4.1.2 Others 4.2 Global PROteolysis Targeting Chimera (PROTAC) Market Size by Application 4.2.1 Global PROteolysis Targeting Chimera (PROTAC) Market Size Overview by Application (2016-2027) 4.2.2 Global PROteolysis Targeting Chimera (PROTAC) Historic Market Size Review by Application (2016-2021) 4.2.2.1 Global PROteolysis Targeting Chimera (PROTAC) Sales Breakdown in Volume, by Application (2016-2021) 4.2.2.2 Global PROteolysis Targeting Chimera (PROTAC) Sales Breakdown in Value, by Application (2016-2021) 4.2.2.3 Global PROteolysis Targeting Chimera (PROTAC) Average Selling Price (ASP) by Application (2016-2021) 4.2.3 Global PROteolysis Targeting Chimera (PROTAC) Forecasted Market Size by Application (2022-2027) 4.2.3.1 Global PROteolysis Targeting Chimera (PROTAC) Sales Breakdown in Volume, by Application (2022-2027) 4.2.3.2 Global PROteolysis Targeting Chimera (PROTAC) Sales Breakdown in Value, by Application (2022-2027) 4.2.3.3 Global PROteolysis Targeting Chimera (PROTAC) Average Selling Price (ASP) by Application (2022-2027) 4.3 Key Regions Market Size Segment by Application 4.3.1 North America PROteolysis Targeting Chimera (PROTAC) Sales Breakdown by Application (2016-2021) 4.3.2 Europe PROteolysis Targeting Chimera (PROTAC) Sales Breakdown by Application (2016-2021) 4.3.3 Asia-Pacific PROteolysis Targeting Chimera (PROTAC) Sales Breakdown by Application (2016-2021) 4.3.4 Latin America PROteolysis Targeting Chimera (PROTAC) Sales Breakdown by Application (2016-2021) 4.3.5 Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Sales Breakdown by Application (2016-2021) 5 North America PROteolysis Targeting Chimera (PROTAC) by Country 5.1 North America PROteolysis Targeting Chimera (PROTAC) Historic Market Size by Country 5.1.1 North America PROteolysis Targeting Chimera (PROTAC) Sales in Volume by Country (2016-2021) 5.1.2 North America PROteolysis Targeting Chimera (PROTAC) Sales in Value by Country (2016-2021) 5.2 North America PROteolysis Targeting Chimera (PROTAC) Forecasted Market Size by Country 5.2.1 North America PROteolysis Targeting Chimera (PROTAC) Sales in Volume by Country (2022-2027) 5.2.2 North America PROteolysis Targeting Chimera (PROTAC) Sales in Value by Country (2022-2027) 6 Europe PROteolysis Targeting Chimera (PROTAC) by Country 6.1 Europe PROteolysis Targeting Chimera (PROTAC) Historic Market Size by Country 6.1.1 Europe PROteolysis Targeting Chimera (PROTAC) Sales in Volume by Country (2016-2021) 6.1.2 Europe PROteolysis Targeting Chimera (PROTAC) Sales in Value by Country (2016-2021) 6.2 Europe PROteolysis Targeting Chimera (PROTAC) Forecasted Market Size by Country 6.2.1 Europe PROteolysis Targeting Chimera (PROTAC) Sales in Volume by Country (2022-2027) 6.2.2 Europe PROteolysis Targeting Chimera (PROTAC) Sales in Value by Country (2022-2027) 7 Asia-Pacific PROteolysis Targeting Chimera (PROTAC) by Region 7.1 Asia-Pacific PROteolysis Targeting Chimera (PROTAC) Historic Market Size by Region 7.1.1 Asia-Pacific PROteolysis Targeting Chimera (PROTAC) Sales in Volume by Region (2016-2021) 7.1.2 Asia-Pacific PROteolysis Targeting Chimera (PROTAC) Sales in Value by Region (2016-2021) 7.2 Asia-Pacific PROteolysis Targeting Chimera (PROTAC) Forecasted Market Size by Region 7.2.1 Asia-Pacific PROteolysis Targeting Chimera (PROTAC) Sales in Volume by Region (2022-2027) 7.2.2 Asia-Pacific PROteolysis Targeting Chimera (PROTAC) Sales in Value by Region (2022-2027) 8 Latin America PROteolysis Targeting Chimera (PROTAC) by Country 8.1 Latin America PROteolysis Targeting Chimera (PROTAC) Historic Market Size by Country 8.1.1 Latin America PROteolysis Targeting Chimera (PROTAC) Sales in Volume by Country (2016-2021) 8.1.2 Latin America PROteolysis Targeting Chimera (PROTAC) Sales in Value by Country (2016-2021) 8.2 Latin America PROteolysis Targeting Chimera (PROTAC) Forecasted Market Size by Country 8.2.1 Latin America PROteolysis Targeting Chimera (PROTAC) Sales in Volume by Country (2022-2027) 8.2.2 Latin America PROteolysis Targeting Chimera (PROTAC) Sales in Value by Country (2022-2027) 9 Middle East and Africa PROteolysis Targeting Chimera (PROTAC) by Country 9.1 Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Historic Market Size by Country 9.1.1 Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Sales in Volume by Country (2016-2021) 9.1.2 Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Sales in Value by Country (2016-2021) 9.2 Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Forecasted Market Size by Country 9.2.1 Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Sales in Volume by Country (2022-2027) 9.2.2 Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Sales in Value by Country (2022-2027) 10 Company Profiles and Key Figures in PROteolysis Targeting Chimera (PROTAC) Business 10.1 Arvinas 10.1.1 Arvinas Corporation Information 10.1.2 Arvinas Introduction and Business Overview 10.1.3 Arvinas PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021) 10.1.4 Arvinas PROteolysis Targeting Chimera (PROTAC) Products Offered 10.1.5 Arvinas Recent Development 10.2 Kymera 10.2.1 Kymera Corporation Information 10.2.2 Kymera Introduction and Business Overview 10.2.3 Kymera PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021) 10.2.4 Arvinas PROteolysis Targeting Chimera (PROTAC) Products Offered 10.2.5 Kymera Recent Development 10.3 C4 therapeutics 10.3.1 C4 therapeutics Corporation Information 10.3.2 C4 therapeutics Introduction and Business Overview 10.3.3 C4 therapeutics PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021) 10.3.4 C4 therapeutics PROteolysis Targeting Chimera (PROTAC) Products Offered 10.3.5 C4 therapeutics Recent Development 10.4 Captor therapeutics 10.4.1 Captor therapeutics Corporation Information 10.4.2 Captor therapeutics Introduction and Business Overview 10.4.3 Captor therapeutics PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021) 10.4.4 Captor therapeutics PROteolysis Targeting Chimera (PROTAC) Products Offered 10.4.5 Captor therapeutics Recent Development 10.5 Vividion 10.5.1 Vividion Corporation Information 10.5.2 Vividion Introduction and Business Overview 10.5.3 Vividion PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021) 10.5.4 Vividion PROteolysis Targeting Chimera (PROTAC) Products Offered 10.5.5 Vividion Recent Development 10.6 Cullgen 10.6.1 Cullgen Corporation Information 10.6.2 Cullgen Introduction and Business Overview 10.6.3 Cullgen PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021) 10.6.4 Cullgen PROteolysis Targeting Chimera (PROTAC) Products Offered 10.6.5 Cullgen Recent Development 10.7 Pfizer 10.7.1 Pfizer Corporation Information 10.7.2 Pfizer Introduction and Business Overview 10.7.3 Pfizer PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021) 10.7.4 Pfizer PROteolysis Targeting Chimera (PROTAC) Products Offered 10.7.5 Pfizer Recent Development 10.8 Merck 10.8.1 Merck Corporation Information 10.8.2 Merck Introduction and Business Overview 10.8.3 Merck PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021) 10.8.4 Merck PROteolysis Targeting Chimera (PROTAC) Products Offered 10.8.5 Merck Recent Development 10.9 Genentech 10.9.1 Genentech Corporation Information 10.9.2 Genentech Introduction and Business Overview 10.9.3 Genentech PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021) 10.9.4 Genentech PROteolysis Targeting Chimera (PROTAC) Products Offered 10.9.5 Genentech Recent Development 10.10 AstraZeneca 10.10.1 Company Basic Information, Manufacturing Base and Competitors 10.10.2 PROteolysis Targeting Chimera (PROTAC) Product Category, Application and Specification 10.10.3 AstraZeneca PROteolysis Targeting Chimera (PROTAC) Sales, Revenue, Price and Gross Margin (2016-2021) 10.10.4 Main Business Overview 10.10.5 AstraZeneca Recent Development 10.11 Amgen 10.11.1 Amgen Corporation Information 10.11.2 Amgen Introduction and Business Overview 10.11.3 Amgen PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021) 10.11.4 Amgen PROteolysis Targeting Chimera (PROTAC) Products Offered 10.11.5 Amgen Recent Development 10.12 Bayer 10.12.1 Bayer Corporation Information 10.12.2 Bayer Introduction and Business Overview 10.12.3 Bayer PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021) 10.12.4 Bayer PROteolysis Targeting Chimera (PROTAC) Products Offered 10.12.5 Bayer Recent Development 11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis 11.1 PROteolysis Targeting Chimera (PROTAC) Key Raw Materials 11.1.1 Key Raw Materials 11.1.2 Key Raw Materials Price 11.1.3 Raw Materials Key Suppliers 11.2 Manufacturing Cost Structure 11.2.1 Raw Materials 11.2.2 Labor Cost 11.2.3 Manufacturing Expenses 11.3 PROteolysis Targeting Chimera (PROTAC) Industrial Chain Analysis 11.4 PROteolysis Targeting Chimera (PROTAC) Market Dynamics 11.4.1 Industry Trends 11.4.2 Market Drivers 11.4.3 Market Challenges 11.4.4 Market Restraints 12 Market Strategy Analysis, Distributors 12.1 Sales Channel 12.2 PROteolysis Targeting Chimera (PROTAC) Distributors 12.3 PROteolysis Targeting Chimera (PROTAC) Downstream Customers 13 Research Findings and Conclusion 14 Appendix 14.1 Research Methodology 14.1.1 Methodology/Research Approach 14.1.1.1 Research Programs/Design 14.1.1.2 Market Size Estimation 14.1.1.3 Market Breakdown and Data Triangulation 14.1.2 Data Source 14.1.2.1 Secondary Sources 14.1.2.2 Primary Sources 14.2 Author Details 14.3 Disclaimer

List of Tables Table 1. Major Company of ARV-110 Table 2. Major Company of ARV-471 Table 3. Major Company of KYM-001 Table 4. Major Company of Others Table 5. Global PROteolysis Targeting Chimera (PROTAC) Sales by Type 2016 VS 2021 VS 2027 (US$ Million) Table 6. Global PROteolysis Targeting Chimera (PROTAC) Sales by Type (2016-2021) & (K Units) Table 7. Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Volume by Type (2016-2021) Table 8. Global PROteolysis Targeting Chimera (PROTAC) Sales by Type (2016-2021) & (US& Million) Table 9. Global PROteolysis Targeting Chimera (PROTAC) Market Share in Value by Type (2016-2021) Table 10. Global PROteolysis Targeting Chimera (PROTAC) Price by Type (2016-2021) & (US$/Unit) Table 11. Global PROteolysis Targeting Chimera (PROTAC) Sales by Type (2022-2027) & (K Units) Table 12. Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Volume by Type (2022-2027) Table 13. Global PROteolysis Targeting Chimera (PROTAC) Sales by Type (2022-2027) & (US$ Million) Table 14. Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Value by Type (2022-2027) Table 15. Global PROteolysis Targeting Chimera (PROTAC) Price by Type (2022-2027) & (US$/Unit) Table 16. North America PROteolysis Targeting Chimera (PROTAC) Sales by Type (2016-2021) & (K Units) Table 17. North America PROteolysis Targeting Chimera (PROTAC) Sales by Type (2016-2021) & (US$ Million) Table 18. Europe PROteolysis Targeting Chimera (PROTAC) Sales (K Units) by Type (2016-2021) Table 19. Europe PROteolysis Targeting Chimera (PROTAC) Sales by Type (2016-2021) & (US$ Million) Table 20. Asia-Pacific PROteolysis Targeting Chimera (PROTAC) Sales (K Units) by Type (2016-2021) Table 21. Asia-Pacific PROteolysis Targeting Chimera (PROTAC) Sales by Type (2016-2021) & (US$ Million) Table 22. Latin America PROteolysis Targeting Chimera (PROTAC) Sales (K Units) by Type (2016-2021) Table 23. Latin America PROteolysis Targeting Chimera (PROTAC) Sales by Type (2016-2021) & (US$ Million) Table 24. Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Sales (K Units) by Type (2016-2021) Table 25. Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Sales by Type (2016-2021) & (US$ Million) Table 26. Global PROteolysis Targeting Chimera (PROTAC) Sales by Company (2016-2021) & (K Units) Table 27. Global PROteolysis Targeting Chimera (PROTAC) Sales Share by Company (2016-2021) Table 28. Global PROteolysis Targeting Chimera (PROTAC) Revenue by Company (2016-2021) & (US$ Million) Table 29. Global PROteolysis Targeting Chimera (PROTAC) Revenue Share by Company (2016-2021) Table 30. Global Market PROteolysis Targeting Chimera (PROTAC) Price by Company (2016-2021) & (US$/Unit) Table 31. Global PROteolysis Targeting Chimera (PROTAC) Top Manufacturers Manufacturing Base Distribution and Sales Area Table 32. Global PROteolysis Targeting Chimera (PROTAC) Manufacturers Market Concentration Ratio (CR5 and HHI) Table 33. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in PROteolysis Targeting Chimera (PROTAC) as of 2020 Table 34. Date of Key Manufacturers Enter into PROteolysis Targeting Chimera (PROTAC) Market Table 35. Key Manufacturers PROteolysis Targeting Chimera (PROTAC) Product Type Table 36. Mergers & Acquisitions, Expansion Plans Table 37. Global PROteolysis Targeting Chimera (PROTAC) Market Size Comparison by Region (US$ Million): 2016 VS 2021 VS 2027 Table 38. Global PROteolysis Targeting Chimera (PROTAC) Sales by Region (2016-2021) & (K Units) Table 39. Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Volume by Region (2016-2021) Table 40. Global PROteolysis Targeting Chimera (PROTAC) Sales by Region (2016-2021) & (US$ Million) Table 41. Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Value by Region (2016-2021) Table 42. Global PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021) Table 43. Global PROteolysis Targeting Chimera (PROTAC) Sales by Region (2022-2027) & (K Units) Table 44. Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Volume by Region (2022-2027) Table 45. Global PROteolysis Targeting Chimera (PROTAC) Sales by Region (2022-2027) & (US$ Million) Table 46. Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Value by Region (2022-2027) Table 47. Global PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2022-2027) Table 48. Global PROteolysis Targeting Chimera (PROTAC) Sales by Application: 2016 VS 2021 VS 2027 (US$ Million) Table 49. Global PROteolysis Targeting Chimera (PROTAC) Sales by Application (2016-2021) & (K Units) Table 50. Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Volume by Application (2016-2021) Table 51. Global PROteolysis Targeting Chimera (PROTAC) Sales by Application (2016-2021) & (US$ Million) Table 52. Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Value by Application (2016-2021) Table 53. Global PROteolysis Targeting Chimera (PROTAC) Price by Application (2016-2021) & (US$/Unit) Table 54. Global PROteolysis Targeting Chimera (PROTAC) Sales by Application (2022-2027) & (K Units) Table 55. Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Volume by Application (2022-2027) Table 56. Global PROteolysis Targeting Chimera (PROTAC) Sales by Application (2022-2027) & (US$ Million) Table 57. Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Value by Application (2022-2027) Table 58. Global PROteolysis Targeting Chimera (PROTAC) Price by Application (2022-2027) & (US$/Unit) Table 59. North America PROteolysis Targeting Chimera (PROTAC) Sales by Application (2016-2021) (K Units) Table 60. North America PROteolysis Targeting Chimera (PROTAC) Sales by Application (2016-2021) & (US$ Million) Table 61. North America PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Value by Application in 2020 Table 62. Europe PROteolysis Targeting Chimera (PROTAC) Sales by Application (2016-2021) (K Units) Table 63. Europe PROteolysis Targeting Chimera (PROTAC) Sales by Application (2016-2021) & (US$ Million) Table 64. Europe PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Value by Application in 2020 Table 65. Asia-Pacific PROteolysis Targeting Chimera (PROTAC) Sales by Application (2016-2021) (K Units) Table 66. Asia-Pacific PROteolysis Targeting Chimera (PROTAC) Sales by Application (2016-2021) & (US$ Million) Table 67. Asia-Pacific PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Value by Application in 2020 Table 68. Latin America PROteolysis Targeting Chimera (PROTAC) Sales by Application (2016-2021) (K Units) Table 69. Latin America PROteolysis Targeting Chimera (PROTAC) Sales by Application (2016-2021) & (US$ Million) Table 70. Latin America PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Value by Application in 2020 Table 71. Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Sales by Application (2016-2021) (K Units) Table 72. Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Sales by Application (2016-2021) & (US$ Million) Table 73. Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Value by Application in 2020 Table 74. North America PROteolysis Targeting Chimera (PROTAC) Sales by Country (2016-2021) & (K Units) Table 75. North America PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Volume by Country (2016-2021) Table 76. North America PROteolysis Targeting Chimera (PROTAC) Sales by Country (2016-2021) & (US$ Million) Table 77. North America PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Value by Country (2016-2021) Table 78. North America PROteolysis Targeting Chimera (PROTAC) Sales by Country (2022-2027) & (K Units) Table 79. North America PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Volume by Country (2022-2027) Table 80. North America PROteolysis Targeting Chimera (PROTAC) Sales by Country (2022-2027) & (US$ Million) Table 81. North America PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Value by Country (2022-2027) Table 82. Europe PROteolysis Targeting Chimera (PROTAC) Sales by Country (2016-2021) & (K Units) Table 83. Europe PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Volume by Country (2016-2021) Table 84. Europe PROteolysis Targeting Chimera (PROTAC) Sales by Country (2016-2021) & (US$ Million) Table 85. Europe PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Value by Country (2016-2021) Table 86. Europe PROteolysis Targeting Chimera (PROTAC) Sales by Country (2022-2027) & (K Units) Table 87. Europe PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Volume by Country (2022-2027) Table 88. Europe PROteolysis Targeting Chimera (PROTAC) Sales by Country (2022-2027) & (US$ Million) Table 89. Europe PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Value by Country (2022-2027) Table 90. Asia-Pacific PROteolysis Targeting Chimera (PROTAC) Sales by Region (2016-2021) & (K Units) Table 91. Asia-Pacific PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Volume by Region (2016-2021) Table 92. Asia-Pacific PROteolysis Targeting Chimera (PROTAC) Sales by Region (2016-2021) & (US$ Million) Table 93. Asia-Pacific PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Value by Region (2016-2021) Table 94. Asia-Pacific PROteolysis Targeting Chimera (PROTAC) Sales by Region (2022-2027) & (K Units) Table 95. Asia-Pacific PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Volume by Region (2022-2027) Table 96. Asia-Pacific PROteolysis Targeting Chimera (PROTAC) Sales by Region (2022-2027) & (US$ Million) Table 97. Asia-Pacific PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Value by Region (2022-2027) Table 98. Latin America PROteolysis Targeting Chimera (PROTAC) Sales by Country (2016-2021) & (K Units) Table 99. Latin America PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Volume by Country (2016-2021) Table 100. Latin America PROteolysis Targeting Chimera (PROTAC) Sales by Country (2016-2021) & (US$ Million) Table 101. Latin America PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Value by Country (2016-2021) Table 102. Latin America PROteolysis Targeting Chimera (PROTAC) Sales by Country (2022-2027) & (K Units) Table 103. Latin America PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Volume by Country (2022-2027) Table 104. Latin America PROteolysis Targeting Chimera (PROTAC) Sales by Country (2022-2027) & (US$ Million) Table 105. Latin America PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Value by Country (2022-2027) Table 106. Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Sales by Country (2016-2021) & (K Units) Table 107. Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Volume by Country (2016-2021) Table 108. Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Sales by Country (2016-2021) & (US$ Million) Table 109. Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Value by Country (2016-2021) Table 110. Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Sales by Country (2022-2027) & (K Units) Table 111. Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Volume by Country (2022-2027) Table 112. Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Sales by Country (2022-2027) & (US$ Million) Table 113. Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Value by Country (2022-2027) Table 114. Arvinas Corporation Information Table 115. Arvinas Introduction and Business Overview Table 116. Arvinas PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021) Table 117. Arvinas PROteolysis Targeting Chimera (PROTAC) Product Table 118. Arvinas Recent Development Table 119. Kymera Corporation Information Table 120. Kymera Introduction and Business Overview Table 121. Kymera PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021) Table 122. Kymera PROteolysis Targeting Chimera (PROTAC) Product Table 123. Kymera Recent Development Table 124. C4 therapeutics Corporation Information Table 125. C4 therapeutics Introduction and Business Overview Table 126. C4 therapeutics PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021) Table 127. C4 therapeutics PROteolysis Targeting Chimera (PROTAC) Product Table 128. C4 therapeutics Recent Development Table 129. Captor therapeutics Corporation Information Table 130. Captor therapeutics Introduction and Business Overview Table 131. Captor therapeutics PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021) Table 132. Captor therapeutics PROteolysis Targeting Chimera (PROTAC) Product Table 133. Captor therapeutics Recent Development Table 134. Vividion Corporation Information Table 135. Vividion Introduction and Business Overview Table 136. Vividion PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021) Table 137. Vividion PROteolysis Targeting Chimera (PROTAC) Product Table 138. Vividion Recent Development Table 139. Cullgen Corporation Information Table 140. Cullgen Introduction and Business Overview Table 141. Cullgen PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021) Table 142. Cullgen PROteolysis Targeting Chimera (PROTAC) Product Table 143. Cullgen Recent Development Table 144. Pfizer Corporation Information Table 145. Pfizer Introduction and Business Overview Table 146. Pfizer PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021) Table 147. Pfizer PROteolysis Targeting Chimera (PROTAC) Product Table 148. Pfizer Recent Development Table 149. Merck Corporation Information Table 150. Merck Introduction and Business Overview Table 151. Merck PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021) Table 152. Merck PROteolysis Targeting Chimera (PROTAC) Product Table 153. Merck Recent Development Table 154. Genentech Corporation Information Table 155. Genentech Introduction and Business Overview Table 156. Genentech PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021) Table 157. Genentech PROteolysis Targeting Chimera (PROTAC) Product Table 158. Genentech Recent Development Table 159. AstraZeneca Corporation Information Table 160. AstraZeneca Introduction and Business Overview Table 161. AstraZeneca PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021) Table 162. AstraZeneca PROteolysis Targeting Chimera (PROTAC) Product Table 163. AstraZeneca Recent Development Table 164. Amgen Corporation Information Table 165. Amgen Introduction and Business Overview Table 166. Amgen PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021) Table 167. Amgen PROteolysis Targeting Chimera (PROTAC) Product Table 168. Amgen Recent Development Table 169. Bayer Corporation Information Table 170. Bayer Introduction and Business Overview Table 171. Bayer PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2016-2021) Table 172. Bayer PROteolysis Targeting Chimera (PROTAC) Product Table 173. Bayer Recent Development Table 174. Key Raw Materials Lists Table 175. Raw Materials Key Suppliers Lists Table 176. PROteolysis Targeting Chimera (PROTAC) Market Trends Table 177. PROteolysis Targeting Chimera (PROTAC) Market Drivers Table 178. PROteolysis Targeting Chimera (PROTAC) Market Challenges Table 179. PROteolysis Targeting Chimera (PROTAC) Market Restraints Table 180. PROteolysis Targeting Chimera (PROTAC) Distributors List Table 181. PROteolysis Targeting Chimera (PROTAC) Downstream Customers Table 182. Research Programs/Design for This Report Table 183. Key Data Information from Secondary Sources Table 184. Key Data Information from Primary Sources List of Figures Figure 1. PROteolysis Targeting Chimera (PROTAC) Product Picture Figure 2. Global PROteolysis Targeting Chimera (PROTAC) Market Size, 2016 VS 2021 VS 2027 (US$ Million) Figure 3. Global PROteolysis Targeting Chimera (PROTAC) Market Size Status and Outlook (2016-2027) & (US$ Million) Figure 4. Global PROteolysis Targeting Chimera (PROTAC) Sales Status and Outlook (2016-2027) & (K Units) Figure 5. Product Picture of ARV-110 Figure 6. Global ARV-110 Sales YoY Growth (2016-2021) & (K Units) Figure 7. Product Picture of ARV-471 Figure 8. Global ARV-471 Sales YoY Growth (2016-2021) & (K Units) Figure 9. Product Picture of KYM-001 Figure 10. Global KYM-001 Sales YoY Growth (2016-2021) & (K Units) Figure 11. Product Picture of Others Figure 12. Global Others Sales YoY Growth (2016-2021) & (K Units) Figure 13. Global PROteolysis Targeting Chimera (PROTAC) Sales by Type (2016-2027) & (US$ Million) Figure 14. Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Volume by Type (2016-2021) Figure 15. Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Value by Type (2016-2021) Figure 16. Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Volume by Type (2022-2027) Figure 17. Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Value by Type (2022-2027) Figure 18. North America PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Volume by Type in 2020 Figure 19. North America PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Value by Type in 2020 Figure 20. Europe PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Volume by Type in 2020 Figure 21. Europe PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Value by Type in 2020 Figure 22. Asia-Pacific PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Volume by Type in 2020 Figure 23. Asia-Pacific PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Value by Type in 2020 Figure 24. Latin America PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Volume by Type in 2020 Figure 25. Latin America PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Value by Type in 2020 Figure 26. Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Volume by Type in 2020 Figure 27. Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Value by Type in 2020 Figure 28. The 5 and 10 Largest Manufacturers in the World: Market Share by PROteolysis Targeting Chimera (PROTAC) Sales in 2020 Figure 29. The 5 and 10 Largest Manufacturers in the World: Market Share by PROteolysis Targeting Chimera (PROTAC) Revenue in 2020 Figure 30. PROteolysis Targeting Chimera (PROTAC) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2016 VS 2020 Figure 31. Product Picture of Oncology Figure 32. Global Oncology Sales YoY Growth (2016-2027) & (K Units) Figure 33. Product Picture of Others Figure 34. Global Others Sales YoY Growth (2016-2027) & (K Units) Figure 35. Global PROteolysis Targeting Chimera (PROTAC) Sales by Application (2016-2027) & (US$ Million) Figure 36. Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Volume by Application (2016-2021) Figure 37. Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Value by Application (2016-2021) Figure 38. Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Volume by Application (2022-2027) Figure 39. North America PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Volume by Application in 2020 Figure 40. Latin America PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Value by Application in 2020 Figure 41. Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Sales Market Share in Value by Application in 2020 Figure 42. Key Raw Materials Price Figure 43. PROteolysis Targeting Chimera (PROTAC) Manufacturing Cost Structure Figure 44. PROteolysis Targeting Chimera (PROTAC) Industrial Chain Analysis Figure 45. Channels of Distribution Figure 46. Distributors Profiles Figure 47. Bottom-up and Top-down Approaches for This Report Figure 48. Data Triangulation Figure 49. Key Executives Interviewed

Arvinas Kymera C4 therapeutics Captor therapeutics Vividion Cullgen Pfizer Merck Genentech AstraZeneca Amgen Bayer